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The role of innate immunity in dementia with Lewy bodies (DLB) has been little studied. We 
investigated the levels in cerebrospinal fluid (CSF) of glial proteins YKL-40, soluble TREM2 (sTREM2) 
and progranulin in DLB and their relationship with Alzheimer’s disease (AD) biomarkers. We included 
patients with DLB (n = 37), prodromal DLB (prodDLB, n = 23), AD dementia (n = 50), prodromal AD 
(prodAD, n = 53), and cognitively normal subjects (CN, n = 44). We measured levels of YKL-40, sTREM2, 
progranulin, Aβ1–42, total tau (t-tau) and phosphorylated tau (p-tau) in CSF. We stratified the group 
DLB according to the ratio t-tau/Aβ1–42 (≥0.52, indicative of AD pathology) and the A/T classification. 
YKL-40, sTREM2 and progranulin levels did not differ between DLB groups and CN. YKL-40 levels were 
higher in AD and prodAD compared to CN and to DLB and prodDLB. Patients with DLB with a CSF 
profile suggestive of AD copathology had higher levels of YKL-40, but not sTREM2 or PGRN, than those 
without. T+ DLB patients had also higher YKL-40 levels than T−. Of these glial markers, only YKL-40 
correlated with t-tau and p-tau in DLB and in prodDLB. In contrast, in prodAD, sTREM2 and PGRN also 
correlated with t-tau and p-tau. In conclusion, sTREM2 and PGRN are not increased in the CSF of DLB 
patients. YKL-40 is only increased in DLB patients with an AD biomarker profile, suggesting that the 
increase is driven by AD-related neurodegeneration. These data suggest a differential glial activation 
between DLB and AD.
Epidemiological, pathological and genetic studies support the importance of the innate immunity in the patho-
physiology of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)1,2. In 
particular, astroglia and microglia play an important role in neurodegeneration3,4. These two cellular types have 
very different functions in the central nervous system (CNS): microglia, the resident monocytic cells in the CNS, 
phagocyte cellular debris and protein aggregates, while astrocytes support neuronal and synaptic activities among 
other key functions3,4.
YKL-40 protein, also known as chitinase 3-like 1 protein, is a glycoprotein expressed by astrocytes near 
amyloid plaques in AD human brain5,6. YKL-40 can be detected in cerebrospinal fluid (CSF) and the lev-
els are increased in preclinical and prodromal AD, as well as in other neurodegenerative conditions, such as 
Frontotemporal Lobar Degeneration (FTLD), Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS)7–10.
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Other studies have implicated the triggering receptor expressed on myeloid cells 2 (TREM2) receptor in 
neurodegenerative diseases11. Rare heterozygous variants in TREM2 have been linked with an increased risk 
of AD12,13. Furthermore, recent studies have shown an elevation in the CSF of the soluble fragment of TREM2 
(sTREM2) in early stages of sporadic AD14–16 as well as in autosomal dominant AD17.
Another line of evidence that supports the role of inflammation in neurodegenerative conditions implicates 
the Progranulin protein (PGRN). PGRN is expressed in many tissues and cell types18. In CNS, PGRN is mainly 
expressed in neurons and microglia18,19 where is involved in the mechanisms of cell proliferation and neuroin-
flammation. PGRN levels are decreased in CSF and blood of patients with heterozygous mutations in the granulin 
gene (GRN), that are associated with FTLD with TAR-DNA-binding protein 43 inclusions20–23. Furthermore, 
genetic variants that modulate GRN expression, such as the GRNrs5848 polymorphism, have been associated 
with an increased risk of AD24,25.
There are multiple evidences that support that glia is activated in synucleinopathies26. In particular, activated 
microglia targeting dopamine nigral neurons has been described in PD27. Microglial activation in PD and demen-
tia with Lewy bodies (DLB) has been implicated in the initiation and progression of the disease by means of secre-
tion of pro-inflammatory cytokines and reactive oxygen species26. In addition, synuclein released from neurons in 
PD and DLB can be endocytosed by astrocytes forming glial inclusions27–29. These inclusions can induce changes 
in gene expression in astroglia, enhancing the inflammatory response and promoting neurodegeneration27,29.
In this study, we investigated the CSF profile of YKL-40, sTREM2, PGRN in patients with DLB and prodromal 
DLB, and compared this pattern with that of AD. We also examined the influence of concomitant AD pathology 
on these biomarkers in DLB.
Results
Demographics and core CSF biomarkers. Table 1 summarizes the demographics and CSF biomarker 
values of all the study participants. There were no significant differences between groups in gender, but CN 
subjects were significantly younger than the other groups. As expected, MMSE scores were lower in DLB and 
AD than in CN or groups with prodAD and prodDLB. Core AD CSF biomarkers also differed between groups 
(Table 1). DLB groups had lower levels of Aβ1–42 than CN but higher than AD groups. DLB groups had also higher 
levels of t-tau and p-tau than CN, but lower than AD groups. Frequency of APOEε4 allele in DLB groups was 
similar to CN and lower than AD groups (p = 0.001).
Relationship between glial biomarkers, age, APOE and clinical measures. There was no associa-
tion between gender and any of the three glial markers, but there was a trend towards higher levels of sTREM2 in 
males (p = 0.06). Therefore, all sTREM2 analyses were adjusted by gender. Age significantly correlated with CSF 
levels of YKL-40 and sTREM2 (r = +0.351; p < 0.001 and +0.212; p < 0.006, respectively) in the whole sample 
CN (n = 44) DLB (n = 37)
Prodromal DLB 
(n = 23) AD (n = 50)
Prodromal AD 
(n = 53) Total p-value
Age, y ± SD 
(range)a
67.4 ± 5.1 
(60.2–78.7)
76.5 ± 5 
(64–84.6)
76.5 ± 6.4 
(58.5–85.8)
74.6 ± 5.6 
(62.4–86.8)
72.3 ± 6.3 
(60.4–85)
73 ± 6.5 
(58.5–86–8) <0.001
Sex, Female % (n) 56.8 (25) 54.1 (20) 56.5 (13) 62 (31) 60.4 (32) 57.8% (78) 0.949
APOEε4, %* (n)b 18.2 (8) 24.3 (9) 34.8 (8) 58 (29) 75 (39) 45.1 (93) 0.003
MMSE ± SDc 28.9 ± 1.2 23 ± 4.6 26.1 ± 2.4 22.5 ± 3.4 26.7 ± 2.3 25.7 ± 3.8 <0.001
Core AD biomarkers
CSF Aβ1–42, pg/
mL ± SDd 918.2 ± 212.2 602.7 ± 269.2 634 ± 197.7 384.7 ± 105.6 458.1 ± 72.2 583.6 ± 261 <0.001
CSF t-tau, pg/
mL ± SDe 228.8 ± 52.3 448.9 ± 333.9 371.3 ± 174.5 694.5 ± 321 609 ± 267.7 493.8 ± 310 <0.001
CSF p-tau, pg/
mL ± SDf 45.5 ± 10.2 68.8 ± 42.3 62.6 ± 24.4 94.1 ± 26.2 94.8 ± 39.2 76 ± 36.8 <0.001
Inflammation-related biomarkers
CSF YKL-40, ng/
mL ± SDg 238.8 ± 49.2 278.8 ± 83.4 270.7 ± 69 295.3 ± 54.1 296.7 ± 55.7 277.8 ± 64.8 <0.001
CSF sTREM2, ng/
mL ± SD (n)h 4.2 ± 2.3 (40) 5.3 ± 2.3 (28) 4.4 ± 1.9 (18) 4.3 ± 2.2 (36) 5 ± 2.4 (41) 4.6 ± 2.3 (163) 0.038
CSF PGRN, ng/
mL ± SD 4.3 ± 1.2 4.2 ± 1.1 4.5 ± 1.3 4.4 ± 1.3 4.6 ± 1.2 4.4 ± 1.2 0.653
Table 1. Demographic and CSF biomarker data. *At least one APOEε4 allele. aCognitively normal controls 
(CN) vs. DLB, prodDLB, AD and prodAD, p < 0.001; prodAD vs. prodDLB and DLB, p = 0.05. bCN, DLB and 
pDLB vs. AD and pAD, p < 0.001. cCN vs. AD, p < 0.001; prodDLB vs. AD, p = 0.09. dCN vs. DLB, prodDLB, 
AD and prodAD and AD vs. DLB and prodDLB, p < 0.001; AD vs. prodAD, p = 0.003. eCN vs. DLB, AD and 
prodAD, p < 0.001; CN vs. prod DLB, p = 0.006; DLB vs. AD and prodAD, p < 0.001; prod DLB vs. AD and 
prod AD, p < 0.001. fCN vs. AD and prodAD, p < 0.001; CN vs. DLB, p = 0.016, CN vs. prodDLB, p = 0.06; 
DLB and prodDLB vs. AD and prodAD, p < 0.001. gCN vs. AD and prodAD, p < 0.01; DLB and prodDLB vs. 
AD, p = 0.03; DLB and prodDLB vs. prodAD, p = 0.006 and p = 0.007, respectively. hpAD vs. AD, p = 0.06 
(results adjusted by multiple comparisons). Analyses using ANCOVA including age for all biomarkers and also 
sex in the case of sTREM2. In post-hoc analyses p-values were adjusted by Bonferroni correction for multiple 
comparisons (10 comparisons for this analysis).
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as previously reported14,17, without differences when stratifying by diagnosis. We did not find differences in the 
levels of any of the glial markers between APOEε4 carriers and non-carriers in the whole group. However, in 
prodDLB, non-carriers showed higher levels of sTREM2 than carriers (5.14 ± 1.9 vs. 3.1 ± 1.1 ng/mL, p = 0.02). 
sTREM2 levels were not influenced by APOEε4 status in any other clinical group. We did not detect differences in 
YKL-40 or PGRN levels between APOEε4 carriers and non-carriers in any clinical group.
We did not find any significant association between the levels of glial markers and the clinical or neuropsycho-
logical measures after correction for multiple comparisons.
Glial biomarkers across clinical diagnoses. Next, we analyzed differences in levels of YKL-40, sTREM2 
and PGRN across groups (Fig. 1, Table 1). We did not find significant differences between DLB, prodDLB and 
CN in the levels of YKL-40 in CSF. Patients with DLB and prodDLB had lower YKL-40 levels than those with AD 
(both p = 0.03) and prodAD patients (p = 0.006 and p = 0.007, respectively). AD and prodAD had significant 
increased levels of YKL-40 compared with CN (both, p < 0.01).
sTREM2 levels did not differ between DLB groups and CN, but levels were higher in both, DLB and prodAD, 
compared to AD (p = 0.02 and p = 0.006, respectively). These differences, however, disappeared when adjusting 
by Bonferroni correction for multiple comparisons and only a trend towards higher sTREM2 levels in prodAD 
compared to AD (p = 0.06) was observed. No differences were found across groups in CSF PGRN levels.
Figure 1. Inflammation-related biomarkers across clinical diagnoses. *p < 0,05, **p < 0.01. The group-wise 
comparisons were analyzed by ANCOVA adjusting by age for all biomarkers and additionally for sex in the case 
of sTREM2. The p-values were adjusted by Bonferroni correction for multiple comparisons (10 comparisons). 
Thicker horizontal bars represent the mean while whiskers represent the standard deviation. CN: cognitively 
normal controls, DLB: Dementia with Lewy Bodies, prodDLB: prodromal DLB, AD: Alzheimer’s disease, 
prodAD: prodromal AD. (a) CSF YKL-40 levels in the different clinical groups. (b) CSF sTREM2 levels in the 
different clinical groups. (c) CSF PGRN levels in the different clinical groups.
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Correlations between glial biomarkers. Figure 2 and Table 2 show the correlations between the three 
investigated glial markers. Supplementary Fig. S1 shows the correlations stratified by diagnosis. We found a cor-
relation between YKL-40 and PGRN levels (r = 0.42, p = 0.01, Fig. 2b) and between sTREM2 and PGRN (r = 0.46, 
p = 0.02, Fig. 2c) in DLB. We also found that YKL-40 correlated with sTREM2 (r = 0.57, p = 0.02, Fig. 2a) in prod-
DLB. In AD groups, we found correlations between YKL-40 and PGRN and sTREM2 and PGRN only in prodAD 
(Fig. 2b,c), but not in AD patients, while YKL-40 and sTREM2 were correlated in both AD and prodAD (Fig. 2a).
Relationship between glial and core AD biomarkers. Table 2 and Supplementary Fig. S2 show the 
different correlations between glial and core AD biomarkers in CSF. YKL-40 correlated with t-tau and p-tau in 
prodDLB (r = 0.71 and r = 0.778, both p < 0.001), and DLB (r = 0.6 and r = 0.627, both p < 0.001). sTREM2 and 
PGRN levels did not correlate with Aβ1–42, t-tau or p-tau in the DLB groups.
Influence of AD copathology on CSF glial markers in DLB. We next analyzed levels of YKL-40, 
sTREM2 and PGRN in DLB patients according to the presence or absence of a CSF AD profile based on the 
ratio t-tau/Aβ1–4230. We found that levels of YKL-40 in DLB patients with a t-tau/Aβ1–42 ratio indicative of AD 
pathophysiology (>0.52) were higher than those with a normal t-tau/Aβ1–42 ratio (<0.52, Fig. 3a, p = 0.04). There 
Figure 2. Correlations between glial biomarkers. CN: cognitively normal controls, DLB: Dementia with Lewy 
Bodies, prodDLB: prodromal DLB, AD: Alzheimer’s disease, prodAD: prodromal AD. (a–c) Correlations 
between CSF sTREM2 and YKL-40, PGRN and YKL-40, and sTREM2 and PGRN levels in the different 
diagnostic groups, r and p-values of the partial correlation are shown in brackets (adjusted by age for all the 
biomarkers and additionally for sex in sTREM2).
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were no differences in the CSF levels of sTREM2 or PGRN in DLB patients when stratifying by the tau/Aβ1–42 
ratio (Fig. 3b,c). Suppl. Table 1 shows demographic and clinical data from those patients. We found similar results 
when analyzing together DLB and prodDLB groups (data nor shown).
To further investigate the influence of amyloid and tau pathology on the CSF levels of glial markers in DLB 
we stratified patients according to the A/T scheme31,32. We did not find differences in glial markers between A+ 
vs. A− DLB patients. T+ DLB patients had higher levels of YKL40 than T- DLB patients (p = 0.007, Fig. 4b). T+ 
DLB patients showed also a trend for higher levels of sTREM2 and PGRN (p = 0.07 and p = 0.09 respectively, 
Fig. 4d,f).
Discussion
The main finding of this study is that YKL-40 levels are elevated in CSF in DLB patients only when there is a CSF 
profile indicative of concomitant AD pathology. The glial markers YKL-40, sTREM2 and PGRN are not increased 
in CSF in DLB when comparing with CN. We also measured for the first time these glial markers in the prodro-
mal phase of DLB and found no increase at this stage of the disease compared to CN and later stages of DLB.
The lack of increase in CSF YKL-40 in the whole DLB group agrees with previous findings in PD and DLB33–37, 
supporting the absence of an increase of this protein in CSF in synucleinopathies. This may suggest a lack of 
astroglial activation following the α-synuclein pathology. On the other hand, our group and others have shown 
an increase of CSF YKL-40 in AD and also FTLD-related syndromes early in the disease course5,7,8,10,35,38,39. This 
contrast between synuclein- and tau-related neurodegenerative dementias suggests that YKL-40 is more involved 
with this second group of disorders. Moreover, we demonstrate an increase in YKL-40 in DLB patients with 
concomitant AD copathology when compared with DLB patients without AD copathology, suggesting that it is 
comorbid AD what is driving astrocytic activation in DLB. In agreement with this finding, we found that YKL-40 
levels were highly correlated with t-tau and p-tau levels in DLB groups and that YKL-40 was increased in T+ DLB 
patients. One possible explanation to the difference in CSF YKL-40 between AD and DLB is that the α-synuclein 
inclusions observed in astrocytes in DLB may influence the astrocytic response toward neurodegeneration com-
pared to tauopathies such as AD and FTLD40,41. In addition, the astrocytic response against pathologic protein 
deposition in DLB seems to be linked to the presence of pathologic tau (p-tau) in the presence of concomitant 
AD pathology.
This is the first study that reports the CSF sTREM2 levels in DLB patients. We found higher levels of this 
protein in DLB compared to AD, but this difference did not survive correction for multiple testing, perhaps due 
to the relatively small sample size that limited the statistical power. Although TREM2 has not been previously 
investigated in postmortem DLB, some studies have shown higher levels of TREM2 in brains of PD patients and 
in PD murine models42–44. This could support the hypothesis that TREM2 is elevated in synucleinopathies in con-
trast to YKL-40. Nevertheless, we could not find differences in sTREM2 levels between DLB and CN. We did not 
find differences either when stratifying the DLB group by CSF AD profile neither a correlation between sTREM2 
and t-tau and p-tau in DLB groups, indicating that the levels of sTREM2 in DLB are independent of neurode-
generation due to AD. We could not replicate previous studies showing higher levels of sTREM2 in AD14,17, with 
only a trend toward higher levels in prodromal AD. These results are possible due to the small number of patients 
included.
Finally, as previously reported in a smaller study33 we did not find any difference in the levels of PGRN protein 
in CSF in DLB or an influence of AD copathology.
One of the strengths of this study is that we included a group of patients with prodromal DLB. Although 
there are no established criteria for this stage of the disease, we included only those patients that converted to 
DLB during the follow-up. YKL-40, sTREM2 and PGRN levels have never been investigated in CSF in prodro-










AD (n = 53) All sample
YKL-40/sTREM2, r 0.524** 0.36 0.569t 0.438* 0.53** 0.406***
YKL-40/PGRN, r −0.332 0.420* 0.294 0.042 0.384* 0.171
sTREM2/PGRN, r 0.162 0.459 0.463 0.276 0.499** 0.337**
YKL-40/Aβ1–42, r 0.423* −0.073 −0.331 0.031 0.101 −0.163*
YKL-40/t-tau, r 0.263 0.600*** 0.71** 0.317 0.65*** 0.572***
YKL-40/p-tau, r 0.285 0.627*** 0.778*** 0.306 0.591*** 0.589***
sTREM2/Aβ1–42, r 0.231 0.196 0.042 0.389t 0.409 0.152
sTREM2/t-tau, r 0.406* 0.235 0.459 0.078 0.418* 0.179*
sTREM2/p-tau, r 0.531** 0.272 0.455 0.155 0.368t 0.204**
PGRN/Aβ1–42, r −0.378t −0.009 −0.129 −0.074 0.210 −0.108
PGRN/t-tau r 0.126 0.339 0.263 0.240 0.393* 0.256***
PGRN/p-tau, r 0.075 0.415t 0.449 0.236 0.394 0.294***
Table 2. Partial correlations between glial markers across diagnoses. r values in bold represent the significant 
correlations between biomarkers. Partial correlations were adjusted by age for all biomarkers and sex in the case 
of sTREM2. P-values were adjusted by Bonferroni correction for multiple comparisons (9 comparisons for this 
analysis). *p < 0.05. **p < 0.01. ***p < 0.001. tp-value between 0.09 and 0.05.
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change significantly early in the disease course. Nonetheless, it is of value to include prodromal DLB patients in 
biomarker studies, not only to find markers of early disease stage, but also to generate new hypothesis regarding 
the pathophysiology of the disease. This study has some limitations: the study is based on CSF biomarkers in a 
single-center cohort and needs validation in a larger independent cohort, the sample size is relatively small, relied 
on clinical diagnosis and neuropathological confirmation was not available.
In summary, we report that DLB and AD show different patterns of glial activation markers in CSF. YKL-40 
is only increased in DLB when there is underlying AD pathology and, in contrast to AD, YKL-40 levels are not 
elevated in prodromal stages. We could not find differences between DLB and healthy subjects in CSF sTREM2 
or PGRN levels, although a trend for higher sTREM2 levels was found compared to AD and independently of 
AD biomarkers. Together, these results suggest a different pattern of glial activation between DLB and AD, which 
needs further functional and molecular studies to elucidate the differential role of this innate immune response 
in DLB and its impact on the disease pathogenesis and progression.
Figure 3. Influence of AD copathology on CSF glial markers in DLB patients. *p-value < 0.05. 
**p-value = 0.009. Thicker horizontal bars represent the mean while whiskers represent the SD. CN: cognitively 
normal controls, DLB: Dementia with Lewy Bodies, Non AD-Sg: DLB patients with core CSF biomarkers non-
suggestive of concomitant AD copathology (t-tau/Aβ1–42 ratio < 0.52). AD-Sg: DLB patients with core CSF 
biomarkers suggestive of concomitant AD copathology (t-tau/Aβ1–42 ratio > 0.52). (a–c) CSF YKL-40, sTREM2 
and PGRN levels in CN and DLB patients with and without AD copathology according to the t-tau/Aβ1–42 ratio.
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Methods
Study participants and clinical classification. We prospectively included 207 subjects evaluated at the 
Memory Unit at Hospital de Sant Pau between January 2009 and October 2017. Patients had the following diag-
noses: DLB (n = 37), prodromal DLB (prodDLB, n = 23), AD dementia (AD, n = 50) and prodromal AD (pro-
dAD, n = 53). We also included 44 cognitively normal controls (CN) selected from the Sant Pau Initiative on 
Neurodegeneration (SPIN) cohort (“https://santpaumemoryunit.com/our-research/spin-cohort/”). To minimize 
the effect of gender and age, AD and prodAD cases were age- and gender-matched with the DLB and prodDLB 
cases. All participants received a clinical and formal neuropsychological assessment45 and underwent lumbar 
puncture to obtain CSF as reported elsewhere30. DLB patients were evaluated using a previously reported clin-
ical protocol45–47. Briefly, the protocol included Minimental State Examination (MMSE), Global Deterioration 
Scale (GDS), Unified Parkinson Disease Rating Scale – part III (UPDRS-III), Boston Naming Test (BNT), Free 
and Cued Selective Reminding Test (FCSRT), Visual Object and Space Perception (VOSP), Trail Making Test 
part A and B (TMT A and B), Neuropsychiatric Inventory (NPI), semantic and phonetic fluencies, Clinician 
Assessment of Fluctuations (CAF) and One Day Fluctuation Assessment Scale (ODFAS). The neurological evalu-
ation also included a structured questionnaire to interrogate about the features and onset of psychotic symptoms 
and sleep47.
Figure 4. CSF glial markers in DLB patients according to A/T classification. *p-value < 0.05. Thicker horizontal 
bars represent the mean while whiskers represent the SD. DLB patients were stratified by levels of Aβ1–42 and 
t-tau in CSF: A+: decreased CSF levels of Aβ1–42, A−: normal CSF levels of Aβ1–42, T+ increased CSF levels of 
p-tau, T− normal CSF levels of p-tau.
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Patients with DLB met consensus criteria for probable DLB48. Patients with prodDLB met general crite-
ria for MCI49 with at least one sign of α-sinucleinopathy (visual hallucinations, parkinsonism, or REM sleep 
behaviour disorder (RBD))50–52 and had to meet criteria of probable DLB48 during the follow up. According to 
current clinical diagnostic criteria48 a diagnosis of DLB excludes a diagnosis of PD by using a one-year rule in 
which dementia have to be present before or at least during the first year of onset of the parkinsonism. DLB 
patients with suspected AD copathology were defined according to the ratio t-tau/Aβ1–42 (≥0.52; indicative of 
underlying AD pathology)30. We also stratified DLB patients according the A/T scheme31,32, considering A+ 
when CSF levels of Aβ1–42 were lower than 550 pg/mL and T+ when CSF levels of p-tau were higher than 61 pg/
mL7 Patients with AD dementia and prodAD met the NIA-AA criteria53,54 and all had a CSF AD profile defined 
by low Aβ1–42 and high t-tau or p-tau levels according to our published cut-offs7. CN were volunteers with a 
normal neuropsychological evaluation for age and education, normal levels of core AD biomarkers in CSF, and 
no cognitive complaints.
CSF collection and analyses. CSF was obtained by lumbar puncture as described7,30. CSF is collected and 
processed in polypropylene tubes following international recommendations. The first 2 ml of CSF are transferred 
to the general laboratory for cell count, and analysis of glucose and protein levels. A further 10 ml are trans-
ferred to our laboratory where samples are processed (centrifuged 2000 g at 4 C, during 10 min) and aliquoted 
within the first two hours after the lumbar puncture. Aliquots are stored at −80 °C until analysis. Levels of core 
AD biomarkers (Aβ1–42, total tau, and phosphorylated tau), YKL-40 and PGRN in CSF were measured using 
commercially available kits from Fujirebio-Europe (InnotestTM, catalog numbers Ref 81583 (Aβ1–42), Ref 81579 
(total tau) and Ref 81581 (phosphorylated tau)), Quidel (catalog number Ref 8020) and Adipogen, Inc. (Catalog 
number AG-45A-0018YEK-KI01), respectively, as previously described7,33,30. sTREM2 levels were measured by 
ELISA using previously described methods14,17,55. Samples were diluted 1:5 to measure sTREM2 and PGRN, 
while were undiluted for the rest of analytes. All samples were randomized across plates, measured in duplicate, 
and all included samples had an intra-assay coefficient of variation (CV) <15%. Inter-assay CV% was <20% for 
all the measured proteins (CVs for each assay are shown in suppl. Table S2). The operator was blinded to clinical 
diagnosis as in previous studies14,17.
APOE genotyping. DNA was extracted using standard procedures and APOE was genotyped accordingly to 
previously described methods56.
Statistical analysis. Differences in categorical variables were assessed by Pearson chi-square tests. 
Normality of the variables was tested by Shapiro-Wilk test. Non-normally distributed variables (sTREM2, YKL-
40, t-tau, and p-tau) were log10-transformed to achieve a normal distribution and all the analyses were performed 
with the log-transformed values. Aβ1–42 did not follow a normal distribution even after log-transformation and 
non-parametric tests were used. Group comparisons between normally distributed values were performed by an 
analysis of covariance (ANCOVA) adjusting by the effect of age. CSF sTREM2 comparisons were additionally 
adjusted by the effect of gender. Partial Pearson Product-Moment correlations controlled by age (and gender in 
CSF sTREM2) were used to test the association between continuous variables. Aβ1–42 differences between groups 
were tested by Kruskal-Wallis and Mann-Whitney tests. Non-parametric correlations (Spearman) were used with 
variables that did not follow normal distribution (MMSE). Bonferroni posthoc correction was applied to adjust 
for multiple comparisons. We considered 10 comparisons when comparing all the clinical groups together and 9 
in the correlations between glial and AD core biomarkers. The level of significance was set at 5% (α = 0.05). All 
statistical analyses were performed using SPSS software version 21.0 for Windows.
Ethical approval and consent to participate. All subjects signed the informed consent form to par-
ticipate in the study and all study protocols were approved by the local ethics committee at Hospital Sant Pau.in 
accordance to Declaration of Helsinki.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on rea-
sonable request.
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